SCHEMBL16146359

SCHEMBL16146359

Nc1nc(NCc2cccc(O)c2O)nc2[nH]cnc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.37
KDM4E B2RXH2 3/20 0.37
MEN1 O00255 2/20 0.37
MAPT P10636 2/20 0.37
KMT2A Q03164 2/20 0.37
NSD2 O96028 1/20 0.37
BLM P54132 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
APP P05067 1/20 0.36
ADORA2A P29274 4/20 0.34
ADORA1 P30542 4/20 0.34
ADORA3 P0DMS8 3/20 0.34
ADORA2B P29275 3/20 0.34
CCNB2 O95067 2/20 0.34
CDK1 P06493 2/20 0.34
CCNB1 P14635 2/20 0.34
CCNB3 Q8WWL7 2/20 0.34
PIM1 P11309 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16146611 0.87 ALDH1A1 (0.39) ALDH1A1KDM4EMEN1MAPTKMT2A
SCHEMBL16146511 0.81 CDK1 (0.40) ALDH1A1KDM4EMEN1MAPTKMT2A
SCHEMBL16146360 0.81 POLA1 (0.44) MAPTADORA3CDK1HSD17B10HTT
SCHEMBL30523400 0.81 POLA1 (0.44) MAPTADORA3CDK1HSD17B10HTT
SCHEMBL16147217 0.81 CCNB2 (0.46) ALDH1A1KDM4EMEN1MAPTKMT2A
SCHEMBL16147003 0.80 LMNA (0.36) MEN1KMT2AL3MBTL1ADORA2AADORA1
SCHEMBL16147251 0.80 MAP4K4 (0.48) ALDH1A1KDM4EMEN1KMT2AL3MBTL1
SCHEMBL16146647 0.80 MAP4K4 (0.49) ADORA2AADORA1ADORA3ADORA2BMAP4K4
SCHEMBL16146363 0.80 MAP4K4 (0.48) ALDH1A1MEN1KMT2AADORA2AADORA1
SCHEMBL16145742 0.79 MAPT (0.38) ALDH1A1KDM4EMEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140303112-A1 Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) ENERGENESIS BIOMEDICAL CO., LTD (TW) 2014-10-09 US claimed
CN-116492347-A Compound for activating AMPK and application thereof 华安医学股份有限公司 2023-07-28 CN disclosed
US-9938279-B2 Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) ENERGENESIS BIOMEDICAL CO., LTD (TW) 2018-04-10 US disclosed
US-20140303112-A1 Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) ENERGENESIS BIOMEDICAL CO., LTD (TW) 2014-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140303112-A1 Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) PRKAG2, PRKAB2, PRKAG1 ALDH1A1 1464/4885KDM4E 3951/4885MEN1 3276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.